Aimmune Therapeutics Inc. (AIMT)

22.43
NASDAQ : Health Technology
Prev Close 21.79
Day Low/High 21.81 / 22.47
52 Wk Low/High 16.95 / 36.12
Avg Volume 516.30K
Exchange NASDAQ
Shares Outstanding 62.67M
Market Cap 1.37B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aimmune Therapeutics Closes $145 Million Investment By Nestlé Health Science

Aimmune Therapeutics Closes $145 Million Investment By Nestlé Health Science

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced the...

Aimmune Therapeutics To Host Investor Symposium Featuring Leading Experts In Peanut Allergy

Aimmune Therapeutics To Host Investor Symposium Featuring Leading Experts In Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that it...

Aimmune Therapeutics Announces Third Quarter 2016 Financial Results And Provides Corporate Update

Aimmune Therapeutics Announces Third Quarter 2016 Financial Results And Provides Corporate Update

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced financial...

Aimmune Therapeutics Announces $145 Million Equity Investment By Nestlé Health Science, Demonstrating Shared Commitment To Advancing Food Allergy Therapeutics

Aimmune Therapeutics Announces $145 Million Equity Investment By Nestlé Health Science, Demonstrating Shared Commitment To Advancing Food Allergy Therapeutics

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy), an approach to treating life-threatening food allergies, today announced...

Aimmune Therapeutics To Participate In Two Upcoming Investor Conferences

Aimmune Therapeutics To Participate In Two Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that...

Aimmune Therapeutics To Participate In Two Upcoming Medical Meetings

Aimmune Therapeutics To Participate In Two Upcoming Medical Meetings

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that it...

Aimmune Therapeutics Completes And Exceeds North American Enrollment Target Ahead Of Schedule In Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy; Company Accelerates Plans For Real-World Experience Study In The U.S.

Aimmune Therapeutics Completes And Exceeds North American Enrollment Target Ahead Of Schedule In Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy; Company Accelerates Plans For Real-World Experience Study In The U.S.

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced early...

Short Interest Jumps 14% For AIMT

Short Interest Jumps 14% For AIMT

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 303,740 share increase in total short interest for Aimmune Therapeutics Inc , to 2,475,743, an increase of 13.98% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Aimmune Therapeutics To Host Conference Call On Potential Positive Implications For AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness In Young Peanut-Allergic Children

Aimmune Therapeutics To Host Conference Call On Potential Positive Implications For AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness In Young Peanut-Allergic Children

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that...

Commit To Purchase Aimmune Therapeutics At $10, Earn 11.9% Annualized Using Options

Commit To Purchase Aimmune Therapeutics At $10, Earn 11.9% Annualized Using Options

Investors considering a purchase of Aimmune Therapeutics Inc shares, but cautious about paying the going market price of $13.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $10 strike, which has a bid at the time of this writing of 40 cents.

Aimmune Therapeutics Announces Second Quarter 2016 Financial Results

Aimmune Therapeutics Announces Second Quarter 2016 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced financial...

Aimmune Therapeutics Stock Sees Short Interest Expand By 14%

Aimmune Therapeutics Stock Sees Short Interest Expand By 14%

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 266,880 share increase in total short interest for Aimmune Therapeutics Inc , to 2,172,003, an increase of 14.01% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Aimmune Therapeutics To Present At The 2016 Wedbush PacGrow Healthcare Conference

Aimmune Therapeutics To Present At The 2016 Wedbush PacGrow Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that...

Aimmune Therapeutics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Aimmune Therapeutics To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that Mary...

Aimmune Therapeutics Appoints Daniel Adelman, M.D., As Chief Medical Officer

Aimmune Therapeutics Appoints Daniel Adelman, M.D., As Chief Medical Officer

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced the...

Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety And Tolerability Profile Of AR101 For Peanut Allergy

Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety And Tolerability Profile Of AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that new...

Aimmune Therapeutics Announces Late-Breaker Presentation At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2016

Aimmune Therapeutics Announces Late-Breaker Presentation At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2016

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that...

Aimmune Therapeutics To Present At Upcoming June Investor Conferences

Aimmune Therapeutics To Present At Upcoming June Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that...

Aimmune Therapeutics Announces First Quarter 2016 Financial Results And Provides Corporate Update

Aimmune Therapeutics Announces First Quarter 2016 Financial Results And Provides Corporate Update

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced financial...

Aimmune Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Aimmune Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized  Oral  Desensitization  Immuno Therapy) treatments for life-threatening food allergies, today...

Aimmune Therapeutics Presents Data On Biomarkers And Potential To Predict Response To Peanut Allergy Treatment With AR101

Aimmune Therapeutics Presents Data On Biomarkers And Potential To Predict Response To Peanut Allergy Treatment With AR101

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that the...

Aimmune Therapeutics Appoints Douglas Sheehy As General Counsel And Secretary

Aimmune Therapeutics Appoints Douglas Sheehy As General Counsel And Secretary

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced the...

Aimmune Therapeutics Announces Phase 2 Follow-On Study Of AR101 For The Treatment Of Peanut Allergy Demonstrated Increased Desensitization And Improved Tolerability With Low-Dose Maintenance

Aimmune Therapeutics Announces Phase 2 Follow-On Study Of AR101 For The Treatment Of Peanut Allergy Demonstrated Increased Desensitization And Improved Tolerability With Low-Dose Maintenance

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™(characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced data from the...

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced financial...

Aimmune Therapeutics To Participate In Two Upcoming Investor Conferences In March

Aimmune Therapeutics To Participate In Two Upcoming Investor Conferences In March

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that members of the senior management team will present a company overview at...

Aimmune Therapeutics To Announce Fourth Quarter And Full Year 2015 Financial Results On Thursday, March 3, 2016

Aimmune Therapeutics To Announce Fourth Quarter And Full Year 2015 Financial Results On Thursday, March 3, 2016

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that its financial results for the fourth quarter and full year 2015 will be...

Aimmune Therapeutics Announces Presentation At The 2016 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Aimmune Therapeutics Announces Presentation At The 2016 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, announced today that the results of ARC002, an open-label Phase 2 continuation trial of...

Aimmune Therapeutics To Present At The 18th Annual BIO CEO & Investor Conference

Aimmune Therapeutics To Present At The 18th Annual BIO CEO & Investor Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly, M.

Aimmune Therapeutics is Now Oversold (AIMT)

Aimmune Therapeutics is Now Oversold (AIMT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aimmune Therapeutics Enrolls First Patient In Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics Enrolls First Patient In Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, announced today that it has enrolled the first patient in the pivotal Phase 3 PALISADE trial of...